Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?

Last week, Swiss pharma giant Novartis (NVS) reported better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates. Core earnings (excluding one-time charges) of $1.98 per share easily beat the Zacks Consensus Estimate of $1.81 and were up from $1.53 reported a year ago.Revenues of $13.15 billion rose 15% from the year-ago reported figure and beat the Zacks Consensus Estimate of $12.97 billion. On a constant currency basis, sales increased 16%, driven by the momentum i ...